LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

23.64 -0.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.15

Max

23.97

Belangrijke statistieken
By Trading Economics
Inkomsten	-2.8M -57M
Verkoop	35K 730K
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-1.1M -63M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+106.29% upside

Dividenden
By Dow Jones
Volgende Winsten	11 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	196M 1.6B
Vorige openingsprijs	24.35
Vorige sluitingsprijs	23.64

Nieuwssentiment

By Acuity

100%

355 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 nov 2025, 23:51 UTC

Winsten

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 nov 2025, 23:10 UTC

Winsten

DBS Third Quarter Net Dips 2.0%

5 nov 2025, 22:55 UTC

Winsten

Arm Holdings 2Q Profit Climbs on Record Demand

5 nov 2025, 22:23 UTC

Winsten

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 nov 2025, 23:52 UTC

Winsten

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 nov 2025, 23:49 UTC

Winsten

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 nov 2025, 23:49 UTC

Winsten

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 nov 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 nov 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 nov 2025, 23:12 UTC

Winsten

Nutrien 3Q Adj EPS 97c >NTR.T

5 nov 2025, 23:11 UTC

Winsten

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 nov 2025, 23:10 UTC

Winsten

Nutrien 3Q Sales $6.01B >NTR.T

5 nov 2025, 23:10 UTC

Marktinformatie

Winsten

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 nov 2025, 23:10 UTC

Winsten

Nutrien 3Q EPS 96c >NTR.T

5 nov 2025, 23:04 UTC

Winsten

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 nov 2025, 23:03 UTC

Marktinformatie

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 nov 2025, 22:55 UTC

Marktinformatie

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 nov 2025, 22:55 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 nov 2025, 22:51 UTC

Winsten

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 nov 2025, 22:50 UTC

Winsten

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 nov 2025, 22:44 UTC

Acquisities, Fusies, Overnames

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 nov 2025, 22:43 UTC

Marktinformatie

Winsten

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 nov 2025, 22:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 nov 2025, 22:36 UTC

Marktinformatie

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 nov 2025, 22:20 UTC

Marktinformatie

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 nov 2025, 22:12 UTC

Acquisities, Fusies, Overnames

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 nov 2025, 22:11 UTC

Acquisities, Fusies, Overnames

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 nov 2025, 22:11 UTC

Acquisities, Fusies, Overnames

Pfizer Responds to Delaware Chancery Court Ruling

5 nov 2025, 22:01 UTC

Winsten

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 nov 2025, 22:01 UTC

Winsten

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

106.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 49.2 USD 106.29%

Hoogste 67 USD

Laagste 25 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.